Pelthos Therapeutics PTHS
NYSE PTHS
$8.97 -0.40 (-4.27%)
As of: Nov 10, 2026 · 3:59 PM EST

Pelthos Therapeutics (PTHS) Research & Development (2023 - 2026)

Updated

Pelthos Therapeutics (PTHS) reported Research & Development of $600,000 for Q2 2026, up 16.5% from $515,000 a year earlier and up 222.6% from the prior quarter.

Analysis

Pelthos Therapeutics (PTHS) Research & Development (2023 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Pelthos Therapeutics' Research & Development came in at $1.31 million, down 7.4% year-over-year; for FY2025, it came in at $1.23 million, up 4.2% from FY2024.

  • Research & Development has a three-year compound annual growth rate of 46.4% (FY2022 to FY2025).
  • By year, Research & Development came in at $1.18 million in FY2024 (-54.3%), $2.58 million in FY2023 (+558.5%) and $391,730 in FY2022.
  • The Q2 2026 figure ranks as the highest quarterly Research & Development since Q4 2023.
  • Year over year, Research & Development gained in three of the last seven quarters, with growth averaging 82.5%.
  • The high point for year-over-year Research & Development in five years was Q3 2024 (growth of 744.7%); the low point was Q4 2024 (a decline of 87.6%).
  • Per Business Quant data, the three quarters before Q2 2026 came in at $186,000 (Q1 2026), $374,000 (Q4 2025) and $145,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 4.25 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 4.65 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 2.57 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 4.54 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 2.85 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 4.05 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 2.11 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 1.61 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 3.02 Bn
10 Pelthos Therapeutics 32.83 Mn -55.57 Mn 11.99 Mn 600,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 600,000.00
Mar 31, 2026 186,000.00
Dec 31, 2025 374,000.00
Sep 30, 2025 145,000.00
Jun 30, 2025 515,000.00
Mar 31, 2025 194,000.00
Dec 31, 2024 285,000.00
Sep 30, 2024 415,000.00
Jun 30, 2024 12,955.00
Mar 31, 2024 466,606.00
Dec 31, 2023 2.29 Mn
Sep 30, 2023 49,132.00
Jun 30, 2023 49,955.00
Mar 31, 2023 186,117.00
API Access

Pelthos Therapeutics Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=PTHS&period=max&api_key=YOUR_API_KEY